Status:
COMPLETED
An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration(FDA)) in the Hispanic population.
Eligibility Criteria
Inclusion
- Male or Female, Hispanic (self-reported), \> 12 years of age
- Moderate to severe asthma requiring treatment with an inhaled corticosteroid
- Diagnosis of asthma for at least 6 months
Exclusion
- Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)
- Any significant disease or disorder that may jeopardize a subject's safety
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
558 Patients enrolled
Trial Details
Trial ID
NCT00419757
Start Date
January 1 2007
End Date
June 1 2008
Last Update
August 27 2012
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Anaheim, California, United States
2
Research Site
Chula Vista, California, United States
3
Research Site
Fresno, California, United States
4
Research Site
Fullerton, California, United States